Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $19.00

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) have earned an average rating of “Buy” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.00.

A number of research firms recently issued reports on IPSC. EF Hutton Acquisition Co. I reaffirmed a “buy” rating and issued a $16.00 target price on shares of Century Therapeutics in a research note on Monday, April 17th. Bank of America reduced their target price on Century Therapeutics from $23.00 to $20.00 in a research note on Friday, March 17th. Chardan Capital reaffirmed a “buy” rating and issued a $19.00 target price on shares of Century Therapeutics in a research note on Wednesday, March 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Century Therapeutics in a research note on Thursday, April 13th.

Insiders Place Their Bets

In other news, insider Luis Borges sold 63,616 shares of the company’s stock in a transaction on Tuesday, March 21st. The stock was sold at an average price of $3.77, for a total transaction of $239,832.32. Following the completion of the sale, the insider now directly owns 43,750 shares in the company, valued at approximately $164,937.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 10.30% of the company’s stock.

Institutional Trading of Century Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Century Therapeutics by 7.9% during the 3rd quarter. BlackRock Inc. now owns 1,409,163 shares of the company’s stock worth $13,936,000 after buying an additional 102,978 shares during the last quarter. Vanguard Group Inc. increased its holdings in Century Therapeutics by 17.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,068,688 shares of the company’s stock valued at $10,569,000 after purchasing an additional 161,713 shares in the last quarter. Geode Capital Management LLC increased its holdings in Century Therapeutics by 2.8% in the 1st quarter. Geode Capital Management LLC now owns 421,177 shares of the company’s stock valued at $1,461,000 after purchasing an additional 11,448 shares in the last quarter. State Street Corp increased its holdings in Century Therapeutics by 7.6% in the 1st quarter. State Street Corp now owns 368,851 shares of the company’s stock valued at $1,280,000 after purchasing an additional 26,180 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in Century Therapeutics by 239.0% in the 4th quarter. Millennium Management LLC now owns 228,858 shares of the company’s stock valued at $1,174,000 after purchasing an additional 161,345 shares in the last quarter. 35.81% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Trading Down 1.2 %

NASDAQ IPSC opened at $3.19 on Tuesday. The business’s 50 day moving average is $3.29 and its two-hundred day moving average is $5.35. Century Therapeutics has a 12-month low of $2.81 and a 12-month high of $14.00. The stock has a market capitalization of $190.06 million, a price-to-earnings ratio of -1.48 and a beta of 0.59.

Century Therapeutics (NASDAQ:IPSC – Get Rating) last released its earnings results on Thursday, March 16th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.05. The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $2.80 million. Century Therapeutics had a negative return on equity of 39.33% and a negative net margin of 2,127.33%. Equities analysts forecast that Century Therapeutics will post -2.04 earnings per share for the current fiscal year.

About Century Therapeutics

(Get Rating)

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.